search
Back to results

Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders

Primary Purpose

Dysplasia, Lip and Oral Cavity Carcinoma, Oral Disorder

Status
Recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Biopsy
Fluorescence Imaging
High-Resolution Microendoscopy
Proflavine Hemisulfate
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Dysplasia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects who are willing to participate.
  • Adult subjects with: a. clinically evident oral premalignant lesion (OPL) or suspicious oral mucosal lesion. or b. pathologic diagnosis of dysplasia or c. history of resected oral cancer or d. oral potentially malignant disorder (OPMD) or e. history of tobacco and/or alcohol exposure.
  • Ability to understand and willingness to sign a written informed consent document (ICD).

Exclusion Criteria:

  • Known allergy to proflavine or acriflavine.
  • Pregnant females.

Sites / Locations

  • M D Anderson Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Diagnostic (multimodal imaging, biopsy)

Arm Description

Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

Outcomes

Primary Outcome Measures

Detection of high grade dysplasia and carcinoma
Will compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD).

Secondary Outcome Measures

Diagnostic assessment
Will determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality.
Biomarker analysis
Will compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection.
Cytologic results
Will compare cytologic results from brush biopsy specimens to white light examination and multimodal imaging results.

Full Information

First Posted
May 26, 2016
Last Updated
August 17, 2023
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02790853
Brief Title
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
Official Title
Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 25, 2016 (Actual)
Primary Completion Date
May 31, 2026 (Anticipated)
Study Completion Date
May 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This early phase I trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders. New types of imaging devices may help doctors decide if a lesion in the mouth is pre-cancerous or cancerous.
Detailed Description
PRIMARY OBJECTIVES: I. To compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD). SECONDARY OBJECTIVES: I. To determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality. II. To compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection. III. To compare cytologic results from brush biopsy specimens to white light examination and multimodal imaging results. OUTLINE: Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years. After completion of study treatment, patients are followed up at 30 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dysplasia, Lip and Oral Cavity Carcinoma, Oral Disorder, Premalignant Lesion

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Diagnostic (multimodal imaging, biopsy)
Arm Type
Experimental
Arm Description
Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.
Intervention Type
Procedure
Intervention Name(s)
Biopsy
Other Intervention Name(s)
Bx
Intervention Description
Undergo brush biopsy and incisional biopsy
Intervention Type
Procedure
Intervention Name(s)
Fluorescence Imaging
Intervention Description
Undergo PS2.1/PS3 imaging
Intervention Type
Procedure
Intervention Name(s)
High-Resolution Microendoscopy
Other Intervention Name(s)
HRME
Intervention Description
Undergo HRME imaging
Intervention Type
Drug
Intervention Name(s)
Proflavine Hemisulfate
Intervention Description
Applied on mucosa
Primary Outcome Measure Information:
Title
Detection of high grade dysplasia and carcinoma
Description
Will compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD).
Time Frame
Up to 2 years
Secondary Outcome Measure Information:
Title
Diagnostic assessment
Description
Will determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality.
Time Frame
Up to 2 years
Title
Biomarker analysis
Description
Will compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection.
Time Frame
Up to 2 years
Title
Cytologic results
Description
Will compare cytologic results from brush biopsy specimens to white light examination and multimodal imaging results.
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects who are willing to participate. Adult subjects with: a. clinically evident oral premalignant lesion (OPL) or suspicious oral mucosal lesion. or b. pathologic diagnosis of dysplasia or c. history of resected oral cancer or d. oral potentially malignant disorder (OPMD) or e. history of tobacco and/or alcohol exposure. Ability to understand and willingness to sign a written informed consent document (ICD). Exclusion Criteria: Known allergy to proflavine or acriflavine. Pregnant females.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ann Gillenwater
Phone
713-792-8441
Email
agillenw@mdanderson.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ann Gillenwater
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
M D Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ann M. Gillenwater
Phone
713-792-8841
First Name & Middle Initial & Last Name & Degree
Ann M. Gillenwater

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
MD Anderson Cancer Center Website

Learn more about this trial

Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders

We'll reach out to this number within 24 hrs